Tonix Pharmaceuticals
TNXP
22 hedge funds and large institutions have $3.63M invested in Tonix Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
22% more capital invested
Capital invested by funds: $2.99M → $3.63M (+$642K)
16% more funds holding
Funds holding: 19 → 22 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.94M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$388K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$69K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$25.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$311K |
| 2 |
Renaissance Technologies
New York
|
-$293K |
| 3 |
Millennium Management
New York
|
-$164K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$123K |
| 5 |
Two Sigma Investments
New York
|
-$77.7K |
TNXP Hedge Fund Activity: Q4 2022 in Review
22 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q4 2022, worth a combined $3.63M — up 22% from $2.99M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TNXP positions and 7 closed out — a net gain of 3 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $1.94M. The largest seller was Morgan Stanley, cutting an estimated $311K.
- 22 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q4 2022, up from 19 in Q3 2022.
- Funds reported $3.63M of Tonix Pharmaceuticals stock for Q4 2022, up 22% quarter-over-quarter.
- 10 funds opened new Tonix Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +3 holders.
- The largest Tonix Pharmaceuticals buyer in Q4 2022 was Tang Capital Management, an estimated $1.94M added.
- The largest Tonix Pharmaceuticals seller in Q4 2022 was Morgan Stanley, an estimated $311K sold.
Based on aggregated 13F filings for Q4 2022.